Mayo Test ID CD33 CD33 Immunostain, Technical Component Only
Ordering Guidance
This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.
Specimen Required
Specimen Type: Tissue
Supplies: Immunostain Technical Only Envelope (T693)
Container/Tube: Immunostain Technical Only Envelope
-Formalin-fixed, paraffin-embedded tissue block
OR
-2 Unstained, positively charged glass slides (25- x 75- x 1-mm) per test ordered; sections 4-microns thick
Acceptable: None
Useful For
Classification of myeloid neoplasms and acute leukemias
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
IHTOI | IHC Initial, Tech Only | No | No |
IHTOA | IHC Additional, Tech Only | No | No |
Method Name
Immunohistochemistry (IHC)
Reporting Name
CD33 IHC, Tech OnlySpecimen Type
TECHONLYSpecimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
TECHONLY | Ambient (preferred) | ||
Refrigerated |
Reject Due To
Wet/frozen tissue Cytology smears Nonformalin fixed tissue Nonparaffin embedded tissue Noncharged slides ProbeOn slides Snowcoat slides |
Reject |
Clinical Information
CD33 (cluster of differentiation 33) is a transmembrane protein that is a member of the sialic acid-binding immunoglobulin-like lactic (Siglec) family. The exact function of CD33 is not known, but it may be involved in cell-to-cell adhesion. It is not expressed on hematopoietic stem cells but is expressed on maturing myelomonocytic cells. As granulocytes mature, there is progressive down regulation of CD33. Monocytes and macrophage/histiocytic cells maintain strong expression of CD33. In normal bone marrow, weak to moderate CD33 staining is seen on granulocytic and monocytic precursors, with strong staining in scattered mast cells. CD33 staining is useful for diagnosis of myeloid neoplasms and classification of acute leukemias. A therapeutic antibody targeting CD33 (gemtuzumab/Myelotarg) is available.
Interpretation
This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.
The positive and negative controls are verified as showing appropriate immunoreactivity. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request; call 855-516-8404.
Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.
Cautions
Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.
The charge of glass slides can be affected by environmental factors and subsequently may alter slide staining. Sending unsuitable glass slides can result in inconsistent staining due to poor slide surface chemistry.
Best practices for storage of positively charged slides:
-Minimize time slides are stored after being unpackaged
-Limit exposure to high humidity and heat
-Minimize exposure to plastics
Clinical Reference
1. Soeno T, Katoh H, Ishii S, et al. CD33+ immature myeloid cells critically predict recurrence in advanced gastric cancer. J Surg Res. 2020;245:552-563
2. Wadai GM, Hussain TA, Hussain MJ. Detect the level of expression of cluster differentiation (CD) marker (CD13 and CD33) in acute myeloid leukemia Iraqi patients. Al-Kufa Univers J Biol. 2016;Special Second International Scientific Conference for the Life Sciences:113-116
3. Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015;29(8):1637-1647
4. Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289-298. doi:10.1007/978-1-4939-8935-5_25
Method Description
Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysSpecimen Retention Time
Until staining is completePerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
88342-TC, primary
88341-TC, if additional IHC
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CD33 | CD33 IHC, Tech Only | Order only;no result |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
70700 | CD33 IHC, Tech Only | Bill only; no result |